Dutch addiction clinics prepare to test a lower-intensity blended model for alcohol use disorder
A pragmatic three-arm randomized trial in Dutch outpatient addiction care is set to examine whether blended treatment for alcohol use disorder can be streamlined without losing clinical value. The protocol, published in BMJ Open as OptiBlend, compares two blended approaches that differ in the number of individual therapy sessions, with the central question focused on whether treatment intensity can be optimized while preserving effectiveness in everyday practice.
The study design matters because alcohol use disorder rarely unfolds in a neat, linear way. Cravings fluctuate, relapse risk rises and falls with stress and cues, and many patients move through care with uneven engagement. A model that combines digital and face-to-face elements has obvious appeal in that setting: it may extend support between visits, reduce the burden on clinicians, and offer more flexible contact for patients who struggle to attend frequent appointments. The protocol is built to test that proposition in a real-world outpatient addiction service rather than in a tightly controlled laboratory environment.
A three-arm design built around treatment intensity
OptiBlend uses a three-arm, pragmatic, single-blinded randomized controlled design. Two treatment arms deliver blended care with different numbers of individual therapy sessions, allowing investigators to compare whether a reduced face-to-face schedule can maintain the benefits of a more intensive approach. The third arm serves as the comparator within the randomization scheme, keeping the trial anchored in a formal assessment of relative effectiveness.
This structure goes beyond a simple question of whether blended care works at all. It asks which version of blended care is clinically efficient enough for outpatient addiction settings, where clinician time, patient adherence, and program capacity all shape what can realistically be delivered. In practice, a treatment model that requires fewer individual sessions but still supports abstinence, drinking reduction, or better treatment engagement could alter how services allocate therapist time without abandoning individualized care.
Blended care is especially relevant to alcohol dependence because many patients need repeated reinforcement to interrupt learned drinking patterns. Digital modules can deliver psychoeducation, self-monitoring, and between-session prompts at the moments when decision-making is most vulnerable. Individual therapy sessions then provide the relational and motivational work that technology cannot replace, including discussion of triggers, coping strategies, and recovery goals. The trial is built around that hybrid logic rather than a wholesale replacement of clinician input.
Patient-centered development shaped the intervention
Patients and therapists were actively involved in developing the optimised blended treatment modules. That feature strengthens the protocol’s relevance because interventions for addiction often fail when they are technically elegant but unusable in routine care. Input from both groups can improve acceptance, reduce friction in implementation, and make the content more compatible with the realities of outpatient practice.
The approach also reflects a basic truth about alcohol use disorder treatment: engagement is a therapeutic mechanism, not just a logistical detail. If a patient stops using the platform, misses appointments, or disengages from homework tasks, the intervention loses force. A treatment model shaped by the people expected to use it is more likely to survive contact with the clinical environment it is meant to serve.
Blinding, self-report, and the limits of pragmatic addiction research
The investigators cannot blind participants or therapists to treatment allocation, a familiar limitation in behavioral and psychotherapeutic trials. Outcome assessors are blinded, which helps reduce detection bias, but the open nature of treatment delivery still leaves room for expectation effects and differential enthusiasm between study arms. In addiction research, those influences can matter because patient motivation and therapeutic alliance can shape reported drinking behavior and treatment retention.
Self-reported outcome measures add another layer of uncertainty. Alcohol consumption is notoriously difficult to measure with perfect accuracy, especially when patients are asked to recall drinking over time or when social desirability may influence answers. Potential variation in treatment adherence and protocol deviations may also affect internal validity. Those are not trivial concerns; they are the price of conducting research in the kind of setting where the findings will ultimately need to hold up.
Why the protocol could change outpatient care if the results hold
The appeal of the trial is not that it seeks a dramatic pharmacologic effect, but that it tests whether the same therapeutic gains might be delivered with fewer in-person sessions. If the less intensive blended arm performs comparably, outpatient programs could potentially expand access, reduce waiting times, and reserve clinician contact for the moments that most benefit from direct interaction. If the reduced-contact arm performs worse, the field will gain a clearer boundary around how far treatment can be compressed before effectiveness begins to erode.
For clinicians, the practical question is whether blended treatment can preserve the core elements that drive recovery: structured monitoring, behavioral rehearsal, accountability, and responsive support when risk escalates. For patients, the question is whether a more flexible model can keep them engaged long enough to disrupt the cycle of repeated heavy drinking, withdrawal relief, and relapse. The protocol is designed to answer both, but only after the trial is completed and the outcomes are measured.
What this protocol leaves unresolved
This publication is a study protocol, not an outcomes paper. It does not establish whether the optimised blended model will outperform, match, or fall short of the more intensive schedule. It also leaves open how robust the model will be across different patient profiles, levels of severity, or patterns of engagement once it is used outside the trial setting.
Still, the trial is clinically relevant because it tackles a question outpatient addiction services face every day: how much direct therapist time is truly necessary when digital support is already part of the treatment package? The answer will depend on whether the streamlined arm can deliver comparable real-world benefit without weakening adherence, accountability, or recovery support. Until those data arrive, the protocol marks an organized attempt to test efficiency without assuming that less contact is automatically enough.